Vertex Pharma stock after-hours at EUR 449.00: minus 0.02 percent versus prior close
Published on 10/05/2026 at 19:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharma stock was at EUR 449.00 after-hours at 7:44 p.m. CEST on October 5, 2026, according to Lang & Schwarz. The price was down 0.02 percent versus the prior close at Lang & Schwarz.
Vertex stock in after-hours trading
Lang & Schwarz listed a prior close of EUR 449.10 for October 2, 2026. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.
Vertex reports kidney disease study results
In a September 22, 2026 release, Vertex Pharmaceuticals Incorporated reported results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease. In the cohort with modest proteinuria, urine albumin to creatinine ratio fell 42.7 percent at Week 13 compared with baseline; in the cohort involving people with type 2 diabetes, it fell 17.3 percent. The company said inaxaplin was generally safe and well tolerated in both cohorts.
Vertex also said it had completed full enrollment in the Phase 2/3 AMPLITUDE trial and remained on track to share interim-analysis results in early 2027 once the relevant cohort reaches 48 weeks of treatment.
